Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans

Date Added
September 7th, 2021
PRO Number
Pro00112888
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Substance Use
Summary

After initial eligibility screening, Veterans who use both cannabis and tobacco will be randomly assigned to receive either varenicline (Chantix) or placebo for 12 weeks. Participants will attend weekly visits to provide breath and urine samples for testing, fill out questionnaires, and meet with study staff about medication compliance.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Clinical Trial of Titrating Doses of Nabilone with Gabapentin for the Mitigation of Cannabis Withdrawal Symptoms

Date Added
September 14th, 2022
PRO Number
Pro00122680
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Substance Use
Summary

This research study will include heavy, long-term cannabis users with moderate to severe use desire who want or need to discontinue cannabis use and have previously had symptoms of cannabis withdrawal. Subjects participating in this research study will receive either PP-01 higher dose or lower dose (combination of nabilone and gabapentin in a varied amount), nabilone only, gabapentin only or placebo (inactive substance). This study will assess whether the study drugs help to lessen or alleviate cannabis withdrawal symptoms in study subjects.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu

A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study to Assess the Efficacy and Safety of Clavulanic Acid vs. Placebo for the Treatment of Cocaine Use Disorder

Date Added
December 19th, 2022
PRO Number
Pro00125021
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Substance Use
Summary

This pilot study is to research whether or not the investigational drug clavulanic acid, along with medication management, can help people with cocaine use disorder who are interested in quitting. Participants who are eligible after screening visits are randomly assigned to take clavulanic acid or placebo for twelve weeks and will meet with study staff three times a week for urine drug screens.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu



-- OR --